Aspirin and a reduced risk of pancreatic cancer have been shown to be linked. Present research indicates regular ingestion of low-dose aspirin may reduce the risk of cancer of the pancreas. Pancreatic cancer in its most common form is called infiltrating ductal adenocarcinoma, and manifests in the pancreas where digestive enzymes are produced. The study citing this information, titled Case Control Study of Aspirin Use and Risk of Pancreatic Cancer was published recently in a medical journal entitled Cancer Epidemiology, Biomarkers & Prevention.
The Yale School of Public Health conducted the study by Dr. Harvey Risch, an epidemiology professor at the school. Data was collected by the team from more than 360 patients with pancreatic cancer and a control group of 690 individuals who were not suffering from the ailment. Enrolled by 30 Connecticut hospitals, the volunteers were studied between 2005 to 2009. Nearly half of the participants were former or current smokers, 19 percent were diagnosed with diabetes within three years prior to the study. Non-Hispanic whites constituted about 92 percent and 52 percent included in the study were men.
The research team classified a “low-dose” of aspirin as being 75 to 325 milligrams, taken to avert heart disease. Those who took low-dose aspirin for more than 10 years showed a 60 percent decrease in the risk of acquiring pancreatic cancer, while those who participated in a six-year study or less had a 39 percent reduction.
The link between Aspirin and the reduction of pancreatic cancer can be linked to dosage and use. Why the low-dose aspirin may be able to reduce pancreatic cancer, risk is currently unknown. What is understood by researchers is aspirin’s disruption with several of the inflammatory pathways in humans, there is speculation that the interruption of the pathways reduces the odds of certain cancers developing, one of which is pancreatic cancer.
According to Dr. Risch, approximately one in 60 adults will get pancreatic cancer at some point in their lives, and the five-year survival rate is less than five percent. Knowing the results of this study, it is critical to discover ways to forestall the onset of pancreatic cancer. He also stated there appears to be sufficient evidence aspirin may also be used to reduce the risk of cardiovascular disease.
Dr. Risch also warns there are future dangers of ingesting aspirin, and guidance from a medical professional prior to starting a regimen is a solid place to start. The use of aspirin has its own potential risks, and each individual person should be evaluated according to their characteristics. Aspirin may cause ulcers, stomach bleeding and bleeding in the brain.
Prospective candidates who might consider using low-dose aspirin are those persons genetically predisposed to pancreatic cancer. On the other hand, Eric Jacobs of the American Cancer Society advised that aspirin is not a proven preventive drug and it is not wise be taken as such. This particular study is one of several articles of research suggesting aspirin could forestall the onset of cancer. Findings of other research indicate the use of aspirin and the reduced risk of pancreatic cancer are linked and it may be advantageous for lowering the risk of ovarian, stomach, esophageal, colorectal, lung and breast cancer as well.
By Andy Towle